Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Key Stats

• Today's Range: $5.52 to $6.32
• 50-Day Range: $3.54 to $9.83
• 52-Week Range: $3.51 to $18.00
• Volume: 133,530 shs
• Average Volume: 82,552 shs
• Market Capitalization: $52.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.50
• Consensus Rating: Buy

Karyopharm Therapeutics Stock Analysis - MarketRank™

Karyopharm Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 318th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Karyopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Karyopharm Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Karyopharm Therapeutics is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Karyopharm Therapeutics is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.11% of the float of Karyopharm Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Karyopharm Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Karyopharm Therapeutics has recently increased by 39.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Karyopharm Therapeutics does not currently pay a dividend.

Dividend Growth

Karyopharm Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

23.11% of the float of Karyopharm Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Karyopharm Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Karyopharm Therapeutics has recently increased by 39.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.19

News Sentiment

Karyopharm Therapeutics has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Karyopharm Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,585.00 in company stock.

Percentage Held by Insiders

Only 2.75% of the stock of Karyopharm Therapeutics is held by insiders.

Percentage Held by Institutions

66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KPTI Stock Analysis - Frequently Asked Questions

How have KPTI shares performed this year?

Karyopharm Therapeutics' stock was trading at $10.1445 at the start of the year. Since then, KPTI stock has decreased by 40.2% and is now trading at $6.07.
View the best growth stocks for 2025 here.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its quarterly earnings results on Wednesday, February, 19th. The company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million.
Read the conference call transcript.

When did Karyopharm Therapeutics' stock split?

Karyopharm Therapeutics shares reverse split before market open on Wednesday, February 26th 2025. The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 4/28/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KPTI
• CIK: 1503802
• Web: www.karyopharm.com
• Phone: (617) 658-0600
• Fax: N/A
• Employees: 380
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $57.50
• High Stock Price Target: $75.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +847.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($15.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-143,100,000.00
• Net Margins: -52.62%
• Pretax Margin: -52.58%
• Return on Equity: N/A
• Return on Assets: -39.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.70
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $145.24 million
• Price / Sales: 0.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.47) per share
• Price / Book: -4.13

Miscellaneous

• Outstanding Shares: 8,570,000
• Free Float: 122,721,000
• Market Cap: $52.02 million
• Optionable: Optionable
• Beta: 0.58